"Myeloablative Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION.
| Descriptor ID |
D019653
|
| MeSH Number(s) |
D27.505.696.477.656.750 D27.505.954.248.589
|
| Concept/Terms |
Myeloablative Agonists- Myeloablative Agonists
- Agonists, Myeloablative
- Myeloablative Agonist
- Agonist, Myeloablative
|
Below are MeSH descriptors whose meaning is more general than "Myeloablative Agonists".
Below are MeSH descriptors whose meaning is more specific than "Myeloablative Agonists".
This graph shows the total number of publications written about "Myeloablative Agonists" by people in this website by year, and whether "Myeloablative Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 2 | 2 | 4 |
| 2018 | 3 | 3 | 6 |
| 2020 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Myeloablative Agonists" by people in Profiles.
-
Mélange intéressante: COVID-19, autologous transplants and multiple sclerosis. Hematology. 2020 Dec; 25(1):320.
-
Successfully treated severe COVID-19 and invasive aspergillosis in early hematopoietic cell transplantation setting. Transpl Infect Dis. 2021 04; 23(2):e13470.
-
Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. J Allergy Clin Immunol. 2020 08; 146(2):300-306.
-
Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation. Int J Hematol. 2019 Feb; 109(2):197-205.
-
Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia. Am J Hematol. 2018 10; 93(10):1211-1219.
-
Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. Blood Adv. 2018 06 12; 2(11):1198-1206.
-
Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMT. Am J Hematol. 2018 07; 93(7):859-866.
-
Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. Cancer. 2018 04 01; 124(7):1428-1437.
-
Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. Am J Hematol. 2018 03; 93(3):416-423.
-
Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2017 Oct; 92(10):997-1003.